Tags

Type your tag names separated by a space and hit enter

Multiple sclerosis, osteoporosis, and vitamin D.
J Neurol Sci 2009; 287(1-2):1-6JN

Abstract

Multiple sclerosis (MS) is associated with reduced bone mass and higher frequency of osteoporosis. Although high-dose short-term intravenous glucocorticoid regimens cause a decrease in bone formation, this effect is usually reversible and osteoporosis in MS patients may be independent of the short-term corticosteroid treatment. Clinical evidence suggests an important role of vitamin D as a modifiable risk factor in MS. Low circulating levels of vitamin D have been found in MS patients, especially during relapses, suggesting that vitamin D could be involved in the regulation of the clinical disease activity. Vitamin D mediates its function through a single vitamin D receptor (VDR). Polymorphisms of the VDR have major effects on vitamin D function and metabolism, and some VDR genotypes have been linked to osteoporosis and MS. Because the safety of high doses of vitamin D has not been established yet, vitamin D hasn't been used in enough doses to increase the serum level to a desired therapeutic target. Future clinical trials should determine the upper limit of vitamin D intake in order to achieve therapeutic benefit in MS patients.

Authors+Show Affiliations

Department of Nuclear Medicine, University Hospital of Ioannina, Ioannina, Greece.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19800081

Citation

Sioka, Chrissa, et al. "Multiple Sclerosis, Osteoporosis, and Vitamin D." Journal of the Neurological Sciences, vol. 287, no. 1-2, 2009, pp. 1-6.
Sioka C, Kyritsis AP, Fotopoulos A. Multiple sclerosis, osteoporosis, and vitamin D. J Neurol Sci. 2009;287(1-2):1-6.
Sioka, C., Kyritsis, A. P., & Fotopoulos, A. (2009). Multiple sclerosis, osteoporosis, and vitamin D. Journal of the Neurological Sciences, 287(1-2), pp. 1-6. doi:10.1016/j.jns.2009.09.012.
Sioka C, Kyritsis AP, Fotopoulos A. Multiple Sclerosis, Osteoporosis, and Vitamin D. J Neurol Sci. 2009 Dec 15;287(1-2):1-6. PubMed PMID: 19800081.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Multiple sclerosis, osteoporosis, and vitamin D. AU - Sioka,Chrissa, AU - Kyritsis,Athanassios P, AU - Fotopoulos,Andreas, Y1 - 2009/10/02/ PY - 2009/06/14/received PY - 2009/08/25/revised PY - 2009/09/10/accepted PY - 2009/10/6/entrez PY - 2009/10/6/pubmed PY - 2010/2/13/medline SP - 1 EP - 6 JF - Journal of the neurological sciences JO - J. Neurol. Sci. VL - 287 IS - 1-2 N2 - Multiple sclerosis (MS) is associated with reduced bone mass and higher frequency of osteoporosis. Although high-dose short-term intravenous glucocorticoid regimens cause a decrease in bone formation, this effect is usually reversible and osteoporosis in MS patients may be independent of the short-term corticosteroid treatment. Clinical evidence suggests an important role of vitamin D as a modifiable risk factor in MS. Low circulating levels of vitamin D have been found in MS patients, especially during relapses, suggesting that vitamin D could be involved in the regulation of the clinical disease activity. Vitamin D mediates its function through a single vitamin D receptor (VDR). Polymorphisms of the VDR have major effects on vitamin D function and metabolism, and some VDR genotypes have been linked to osteoporosis and MS. Because the safety of high doses of vitamin D has not been established yet, vitamin D hasn't been used in enough doses to increase the serum level to a desired therapeutic target. Future clinical trials should determine the upper limit of vitamin D intake in order to achieve therapeutic benefit in MS patients. SN - 1878-5883 UR - https://www.unboundmedicine.com/medline/citation/19800081/Multiple_sclerosis_osteoporosis_and_vitamin_D_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0022-510X(09)00854-5 DB - PRIME DP - Unbound Medicine ER -